Claris
   Select Language : myClaris
Claris Lifesciences Limited - India

  Career                :   Contact Us
India's Best Companies to Work for 2010


 

 

2010 | 2009 | 2008
November
Claris sets up new anti-infective injectable unit
September
Claris on Fast Track
July
Claris organizes a “3” day training session for “380” newly recruited Traffic Assistants of the city
May
Claris partners Pfizer to strengthen regulated market presence
April
Eyeing the niche
February
Walking through the labyrinth

After Pfizer deal, Claris on fast track

Times of India,Ahmedabad, September 10, 2009
Investing Rs 200 Cr To Make 50 New Products

Nimish Shukla TNN

Ahmedabad: After clinching the partnership deal with US-based drug giant Pfizer, Claris Lifesciences Ltd, an Ahmedabad-based pharma player specialising in manufacturing sterile injectables, is now setting up two new facilities with an investment of Rs 200 crore for entering in a new therapeutic segments like anti-infective, pain management, anaesthesia, oncology and renal care.
The new facilities, which will be coming up at the company’s existing state-of-theart manufacturing plant at Changodar on the outskirts of the city, are expected to be functional in two years time. With commissioning of the new plants,Clariswillbe able to manufacture 50 new products in the new therapeutic segments. At present, it manufactures 75 products in various segments.

“The expansion will help us take our topline from Rs 750 crore to Rs 1,200 crore in the next three year and our deal with Pfizer is expected to contribute around 15-20% in our revenue growth,” Arjun Handa, managing director and CEO, Claris Lifesciences told TOI.
The company in May 2009 inked the partnership deal with Pfizer to get access to regulated markets like US and Europe by leveraging its manufacturing facilities and products.

The company already has about 800 registrations in the international markets and with this expansion plan is intends to add another 500 registrations. The growth will primarily come from the regulated markets like US and Europe along with new markets being opened up like Russia, Turkey and others, Handa added.

At present, the company has global footprint across 76 countries, operating in the critical care segment, with special focus on high-end injectables, including sterile parenteral preparations, life saving medicines and other hospital products for the treatment of critical illnesses and diseases.

The company has a total workforce of 2,000 people and new expansion will add to add a headcount of 800. The expansion cost will be met through mixture of internal accruals and debt, Handa said.
Useful Links   Products   Manufacturing   Capabilities   Investors   Media
Home
About Us
Partner Us
Career
Contact Us
Anesthesia
Nutrition
Plasma Volume
Expanders

Blood Product
Anti-Infectives
Renal & Transplant
Oncology
Infusion Therapy
Select Injectables
Emotional
Pharmacopoeia

Facilities
Regulatory
Delivery Systems
R&D / F&D
Investors
Investor FAQs
Corporate
Governance

Board of Directors'
Profile

Key Management
Personnel

Statutory Compliance
Photo Gallery
Investor Contact

Press Room
Press Kit
Media Contact
 
Claris Lifesciences Ltd. All Rights Reserved.  :: Terms of Use  :: Privacy Policy :: Sitemap